Treatment of vaginal candidiasis with a single oral dose of fluconazole

  • Multicentre Study Group


A single dose of 150 mg fluconazole was used to treat 180 patients with clinical and mycological evidence of vaginal candidiasis in an open, non-comparative, multicentre trial. The clinical response to treatment was excellent, with 97 % of patients cured or markedly improved after 5 to 16 days. At long-term assessment (27 to 62 days), the proportion cured was 88 %. Candida was eradicated from the vagina in 93 % of patients at short-term assessment and in 73 % at long-term assessment. The rate of relapse, reinfection or recolonization at long-term assessment in patients who had responded at short-term assessment was 23 %. The incidence of side-effects was low, and consisted mainly of mild gastrointestinal complaints. Abnormal laboratory test results occurred in 15 of 167 evaluable patients, but all were minor and of minimal clinical significance. Oral fluconazole given in a single dose of 150 mg is an effective, safe and well tolerated treatment for vaginal candidiasis.


Single Dose Clinical Response Oral Dose Fluconazole Candidiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bisschop, M. P. J. M., Merkus, J. M. W. M., Scheygrond, H., Van Cutsem, J., Van de Kuy, A. Treatment of vaginal candidiasis with ketoconazole, a new orally active antimycotic. European Journal of Obstetrics, Gynaecology, and Reproductive Biology 1979, 9: 253–258.Google Scholar
  2. 2.
    Van der Pas, H., Peeters, F., Janssens, D., Schauwaert, E., Van Cutsem, J. Treatment of vaginal candidiasis with oral ketoconazole. European Journal of Obstetrics, Gynaecology, and Reproductive Biology 1983, 14: 399–404.Google Scholar
  3. 3.
    Pont, A., Williams, P. L., Loose, D. S., Feldman, D., Reitz, R. E., Bochra, C., Stevens, D. A. Ketoconazole blocks adrenal steroid synthesis. Annals of Internal Medicine 1982, 97: 370–372.PubMedGoogle Scholar
  4. 4.
    Hawkins Van Tyle, J. Ketoconazole. Pharmacotherapy 1984, 4: 343–373.PubMedGoogle Scholar
  5. 5.
    Janssen, P. A. J., Symeons, J. E. Hepatic reactions during ketoconazole treatment. American Journal of Medicine 1983, 74: 80–85.CrossRefPubMedGoogle Scholar
  6. 6.
    Richardson, K., Brammer, K. W., Marriott, M. S., Troke, P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections withCandida albicans andTrichophyton mentagrophytes. Antimicrobial Agents and Chemotherapy 1985, 27: 832–835.PubMedGoogle Scholar
  7. 7.
    Humphrey, M. J., Jevons, S., Tarbit, M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy 1985, 28: 648–653.PubMedGoogle Scholar
  8. 8.
    Faccini, J. M., Bennett, P. N., Reid, J. L. European ethical review committee: the experience of an international ethics committee reviewing protocols for drug trials. British Medical Journal 1984, 289: 1052–1054.PubMedGoogle Scholar
  9. 9.
    Miles, M. R., Olsen, L., Rogers, A. Recurrent vaginal candidiasis. Importance of an intestinal reservoir. Journal of the American Medical Association 1977, 238: 1836–1837.CrossRefPubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1988

Authors and Affiliations

  • Multicentre Study Group

There are no affiliations available

Personalised recommendations